<DOC>
	<DOCNO>NCT01921712</DOCNO>
	<brief_summary>The purpose study assess safety tolerability PUR0200 . In addition , study look blood level different dos PUR0200 affect lung function COPD patient .</brief_summary>
	<brief_title>A Safety , Pharmacokinetic Pharmacodynamic Study PUR0200 COPD Patients</brief_title>
	<detailed_description>This multi-center , 2-part , pharmacokinetic ( PK ) , pharmacodynamic ( PD ) effect , safety tolerability study single dos PUR0200 .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<criteria>Key A clinical diagnosis moderate severe COPD accord follow criterion : Current exsmokers least 10 packyear smoke history Postbronchodilator FEV1 &gt; /= 35 % &lt; /= 80 % predict normal value Postbronchodilator FEV1/FVC ( force vital capacity ) ratio &lt; 0.70 Postbronchodilator improvement FEV1 &gt; /= 100 mL Key Current evidence recent history clinically significant unstable disease ( COPD ) Current diagnosis asthma Presence history clinically significant allergy require treatment COPD exacerbation within 6 week Use daily oxygen therapy &gt; 10 hour Thoracotomy pulmonary resection Use systemic steroid within 3 month Lower respiratory tract infection within 30 day Upper respiratory tract infection within 30 day require treatment antibiotic History tuberculosis , bronchiectasis , nonspecific pulmonary disease Prolonged correct QT ( QTc ) interval &gt; 450 msec male &gt; 470 msec female , history long QT syndrome</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>COPD</keyword>
	<keyword>Chronic Obstructive Pulmonary Disease</keyword>
</DOC>